Publications by authors named "Nicolas Isambert"

94Publications

Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer.

Eur J Cancer 2019 10 6;120:97-106. Epub 2019 Sep 6.

Platform of Transfer in Biology of Cancer, Georges Francois Leclerc Cancer Center, 1 Rue Du Professeur Marion, 21000 Dijon, France; GIMI Genetic and Immunology Medical Institute, 21000 Dijon, France; Department of Medical Oncology, Georges Francois Leclerc Cancer Center, 1 Rue Du Professeur Marion, 21000 Dijon, France; INSERM U1231, Dijon, France; Univ. Bourgogne Franche-Comté, Dijon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.07.020DOI Listing
October 2019

Health-related quality of life as an endpoint in oncology phase I trials: a systematic review.

BMC Cancer 2019 Apr 16;19(1):361. Epub 2019 Apr 16.

Methodology and Quality of Life in Oncology Unit, INSERM UMR 1098, University Hospital of Besançon, Besançon, France.

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-019-5579-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469065PMC
April 2019

Low Cross-Reactivity Between Cisplatin and Other Platinum Salts.

J Allergy Clin Immunol Pract 2019 Jul - Aug;7(6):1894-1900. Epub 2019 Feb 15.

Dermatology Department, Dijon University Hospital, Dijon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2019.01.057DOI Listing
September 2020

Glyceryl trinitrate‑induced cytotoxicity of docetaxel‑resistant prostatic cancer cells is associated with differential regulation of clusterin.

Int J Oncol 2019 Apr 1;54(4):1446-1456. Epub 2019 Feb 1.

Laboratoire d'Immunologie et Immunothérapie des Cancers, EPHE, PSL Research University, F‑75000 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2019.4708DOI Listing
April 2019

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.

Cancer Chemother Pharmacol 2018 12 22;82(6):979-986. Epub 2018 Oct 22.

Institut Universitaire du Cancer de Toulouse, Oncopôle, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3689-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267664PMC
December 2018

Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial.

JCO Precis Oncol 2018 19;2. Epub 2018 Oct 19.

, , , , , , , , , , , , , , , , , and , Institut Curie, Paris; , , , , , , , , , , , , , and , Institut Curie; , Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; , Institut Paoli-Calmettes, Marseille; , Centre Léon Bérard, Lyon; , Centre Alexis Vautrin, Nancy; , Institut Claudius Régaud, Toulouse; , Centre René Gauducheau, Nantes; , Centre Georges-François Leclerc, Dijon; and , Versailles-Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.18.00048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450915PMC
October 2018

Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.

Br J Clin Pharmacol 2018 12 10;84(12):2877-2888. Epub 2018 Oct 10.

Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Waltham, MA, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bcp.13753
Publisher Site
http://dx.doi.org/10.1111/bcp.13753DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256010PMC
December 2018

Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.

Invest New Drugs 2018 12 29;36(6):1044-1059. Epub 2018 May 29.

Institut Universitaire du Cancer de Toulouse-Oncopole and Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0601-1DOI Listing
December 2018

Exosomes in cancer theranostic: Diamonds in the rough.

Cell Adh Migr 2017 03 6;11(2):151-163. Epub 2017 Feb 6.

a INSERM, UMR 866, Laboratoire d'Excellence LipSTIC , Dijon , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/19336918.2016.1250999DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351734PMC
March 2017

Pharmacokinetic interaction between pazopanib and cisplatin regimen.

Cancer Chemother Pharmacol 2016 Feb 16;77(2):385-92. Epub 2016 Jan 16.

Institut Claudius-Regaud, IUCT-O, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2953-yDOI Listing
February 2016

Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer.

J Natl Cancer Inst 2016 Mar 22;108(3). Epub 2015 Nov 22.

Affiliations of authors:INSERM, UMR 866, Laboratoire d'Excellence LipSTIC , Dijon , France (JG, GM, MC, AMMD, NP, AH, SR, HM, NI, VC, CR, FL, FG, AdT, RS, CG); Faculty of Medicine and Pharmacy, University of Burgundy , Dijon , France (JG, GM, MC, AMMD, NP, AH, SR, HM, NI, VC, CR, FL, FG, AdT, RS, CG); Department of Medical Oncology, Georges-François Leclerc Centre , Dijon , France (JG, NI, CR, AB, VG, FG, PF, CG); Department of Biostatistics, Georges-François Leclerc Centre , Dijon , France (AB); CHU , Dijon , France (FL); Equipe Labellisée par la Ligue Nationale contre le Cancer (CG).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/108/3/djv330.full.pdf
Web Search
http://jnci.oxfordjournals.org/lookup/doi/10.1093/jnci/djv33
Publisher Site
http://dx.doi.org/10.1093/jnci/djv330DOI Listing
March 2016

Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.

J Clin Oncol 2015 Sep 27;33(25):2797-802. Epub 2015 Jul 27.

Isabelle L. Ray-Coquard, Philippe A. Cassier, and Jean-Yves Blay, Centre Léon Bérard and Claude Bernard University, Lyon; Julien Domont, Olivier Mir, and Axel Le Cesne, Gustave Roussy, Villejuif; Emmanuelle Tresch-Bruneel and Stéphanie Clisant, Centre Oscar Lambret; Nicolas Penel, Centre Oscar Lambret and Lille-Nord-de-France Medical School, Lille; Emmanuelle Bompas, Centre René Gauducheau, Nantes; Sophie Piperno-Neumann, Institut Curie, Paris; Antoine Italiano, Institut Bergonié, Bordeaux; Christine Chevreau, Institut Claudius Regaud, Toulouse; Didier Cupissol, Institut de Cancérologie de Montpellier, Val d'Aurelle, Montpellier; François Bertucci, Institut Paoli Calmette, Marseille; Jacques-Olivier Bay, Centre Jean Perrin, Clermont-Ferrand; Olivier Collard, Institut de Cancérologie de la Loire Lucien Neuwirth, Saint Priest en Jarez; Esma Saada-Bouzid, Centre Antoine Lacassagne, Nice; Nicolas Isambert, Centre Georges-François Leclerc, Dijon; and Corinne Delcambre, Centre François Baclesse, Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.8505DOI Listing
September 2015

A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer.

Breast Cancer Res Treat 2013 Jul 25;140(1):73-82. Epub 2013 Jun 25.

Department of Cancer and Surgery, Faculty of Medicine, ICTEM, Imperial College London, Room 145, Du Cane Road, London, W12 0NN, UK,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-013-2597-8DOI Listing
July 2013

Degarelix as a new antiangiogenic agent for metastatic colon cancer?

World J Gastroenterol 2013 Feb;19(5):769-72

Unite Mixte de Recherche 866, Institut National de la Sante et de la Recherche Medicale/Universite de Bourgogne, 21000 Dijon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v19.i5.769DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574605PMC
February 2013

Osteosarcomas of the mandible: are they different from other tumor sites?

Crit Rev Oncol Hematol 2012 Jun 24;82(3):280-95. Epub 2011 Aug 24.

Department of Radiation Oncology/IBDC CNRS UMR 6543, Cancer Center Antoine-Lacassagne - Institut Universitaire de la Face et du Cou, University Nice Sophia-Antipolis, 33 Av. Valombrose, 06189 NICE Cedex 2 France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2011.07.001DOI Listing
June 2012

Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.

Invest New Drugs 2012 Apr 4;30(2):653-61. Epub 2010 Nov 4.

Département de Cancérologie Générale, Centre Oscar Lambret, 3 Rue F Combemale, 59020 Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9574-4DOI Listing
April 2012

Multicomponent reactions and ionic liquids: a perfect synergy for eco-compatible heterocyclic synthesis.

Chem Soc Rev 2011 Mar 20;40(3):1347-57. Epub 2010 Oct 20.

Aix-Marseille Université-Institut des Sciences Moléculaires de Marseille-UMR CNRS 6263 iSm2, Centre Saint Jérôme, Service 531, 13397, Marseille Cedex 20, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c0cs00013bDOI Listing
March 2011

Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates.

Chem Biol Interact 2010 Sep 16;187(1-3):411-5. Epub 2010 Feb 16.

Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, and Institut de Biomedicina (IBUB), Universitat de Barcelona, Av. Diagonal 643, E-08028 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cbi.2010.02.013DOI Listing
September 2010

"Classical 3 + 3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agents.

Invest New Drugs 2009 Dec 10;27(6):552-6. Epub 2009 Jan 10.

Département de Cancérologie Générale, Centre Oscar Lambret, 3, Rue F Combemale, 59020, Lille, France.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-008-9213-5
Publisher Site
http://dx.doi.org/10.1007/s10637-008-9213-5DOI Listing
December 2009

Benzimidazolium salts as small, nonpeptidic and BBB-permeable human prolyl oligopeptidase inhibitors.

ChemMedChem 2008 Oct;3(10):1558-65

Institute for Research in Biomedicine, Barcelona Science Park, Josep Samitier 1-5, 08028 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cmdc.200800152
Publisher Site
http://dx.doi.org/10.1002/cmdc.200800152DOI Listing
October 2008

Heterocycles as key substrates in multicomponent reactions: the fast lane towards molecular complexity.

Chemistry 2008 ;14(28):8444-54

Institute for Research in Biomedicine, Barcelona Science Park, Baldiri Reixac 10-12, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/chem.200800473DOI Listing
November 2008

[Angiogenesis targeting in breast cancer].

Bull Cancer 2007 ;94(7 Suppl):F199-206

Centre Georges-François Leclerc, rue du Professeur-Marion, 21079 Dijon.

View Article

Download full-text PDF

Source
December 2007

Enol esters: versatile substrates for Mannich-type multicomponent reactions.

Org Lett 2007 Oct 15;9(21):4199-202. Epub 2007 Sep 15.

Institute for Research in Biomedicine, Barcelona Science Park, Josep Samitier 1-5, 08028 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/abs/10.1021/ol701717z
Publisher Site
http://dx.doi.org/10.1021/ol701717zDOI Listing
October 2007

Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.

Breast 2008 Feb 14;17(1):36-41. Epub 2007 Aug 14.

Department of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur Marion, 21000 Dijon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2007.06.003DOI Listing
February 2008

Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.

Cancer Chemother Pharmacol 2002 Jun 20;49(6):445-52. Epub 2002 Apr 20.

Unité INSERM 517, Faculté de Médecine et de Pharmacie, 7 bd Jeanne d'Arc, BP 87900, 21079 Dijon, France.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-002-0450-6
Publisher Site
http://dx.doi.org/10.1007/s00280-002-0450-6DOI Listing
June 2002